Merus (NASDAQ:MRUS) had its target price decreased by research analysts at Citigroup from $18.00 to $16.00 in a report released on Thursday, March 21st, BenzingaRatingsTable reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Citigroup‘s price objective suggests a potential downside of 2.74% from the stock’s current price.
Several other equities research analysts also recently weighed in on the stock. BidaskClub upgraded shares of Merus from a “strong sell” rating to a “sell” rating in a research note on Friday, March 1st. ValuEngine upgraded shares of Merus from a “sell” rating to a “hold” rating in a research note on Wednesday, March 6th. Finally, Zacks Investment Research downgraded shares of Merus from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.
NASDAQ:MRUS traded up $1.73 during trading hours on Thursday, hitting $16.45. The company’s stock had a trading volume of 44,600 shares, compared to its average volume of 30,665. The firm has a market capitalization of $349.21 million, a PE ratio of -8.94 and a beta of -0.06. Merus has a 52-week low of $11.00 and a 52-week high of $26.74.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Featured Story: What is the price-sales ratio?
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.